KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN G...
- Written by LATEST ASIANET NEWS RELEASES
- Category: Asia Net
SYDNEY, Sept. 9, 2022 /PRNewswire-Asianet/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral pr......




